Terms: = Head and neck cancer AND KMT2D, ENSG00000167548, 8085, MLL2 AND Clinical Outcome
3 results:
1. Oncoproteomic and gene expression analyses identify prognostic biomarkers for second primary malignancy in patients with head and neck squamous cell carcinoma.
Bunbanjerdsuk S; Vorasan N; Saethang T; Pongrujikorn T; Pangpunyakulchai D; Mongkonsiri N; Arsa L; Thokanit N; Pongsapich W; Anekpuritanang T; Ngamphaiboon N; Jinawath A; Sunpaweravong S; Pisitkun T; Suktitipat B; Jinawath N
Mod Pathol; 2019 Jul; 32(7):943-956. PubMed ID: 30737471
[TBL] [Abstract] [Full Text] [Related]
2. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract] [Full Text] [Related]
3. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Choi M; Kadara H; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Kim K; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Herbst RS; Wistuba II
Ann Oncol; 2017 Jan; 28(1):83-89. PubMed ID: 28177435
[TBL] [Abstract] [Full Text] [Related]
